(1088–1122) Immunological Complications of Medical Therapy Poster

Monday, October 27, 2025

10:30 AM - 12:30 PM Central Time

Location: Hall F1

CE: 0.00

Presentations:

10:30 AM - 12:30 PM Central Time

A Retrospective Study of Adverse Cardiovascular Events in Patients Started on JAK Inhibitors at Two Major Health Systems in Northeast Ohio: Analysis of the 2019 JAK Inhibitors FDA Boxed Warning for Increased Risk of Serious Heart-related Problems
Abstract Poster Presenter: William Koch, PhD, DO – University Hospitals
10:30 AM - 12:30 PM Central Time

Association Between Pre-existing Rheumatoid Arthritis and Immune-related Adverse Events in Patients with Cancer Receiving Immune Checkpoint Inhibitors
Abstract Poster Presenter: KEVIN SHENG- KAI MA, DDS – Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
10:30 AM - 12:30 PM Central Time

Associations Between Pre-existing Autoimmunity and CAR T Cell Therapy Toxicity for Cancer Treatment: A Nationwide Retrospective Cohort Study
Abstract Poster Presenter: Gregory Challener, MD – Massachusetts General Hospital
10:30 AM - 12:30 PM Central Time

Baseline Data on Rheumatic Immune-related Adverse Events from the Largest Prospective Multicenter US Consortium
Abstract Poster Presenter: Laura Cappelli, MD – Johns Hopkins School of Medicine
10:30 AM - 12:30 PM Central Time

Baseline Features, Immunosuppression, and Immune-related Adverse Events in Patients with Pre-existing Rheumatic Disease and Cancer Requiring Immune Checkpoint Inhibitor Therapy
Abstract Poster Presenter: Laura Cappelli, MD – Johns Hopkins School of Medicine
10:30 AM - 12:30 PM Central Time

Breaking Bones, Breaking Hearts: A FAERS Perspective on Osteoporosis Medications
Abstract Poster Presenter: Manush Sondhi, MD (he/him/his) – University of Washington
10:30 AM - 12:30 PM Central Time

Changes in NK cells and TH cell phenotype in Rheumatoid Arthritis patients treated with janus kinase inhibitors: implications for adverse effects
Abstract Poster Presenter: Carmen Lasa Teja, n/a – Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain.
10:30 AM - 12:30 PM Central Time

Characteristics of SARS-CoV-2 infected Patients with Rheumatic Diseases on Rituximab: A Subanalysis of the COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) Study
Abstract Poster Presenter: Laurianne Simard, MD (she/her/hers) – Université Laval
10:30 AM - 12:30 PM Central Time

Checkpoint Inhibitor Induced Myocarditis with Myositis/Myasthenia Gravis Concurrence: An Observational Study
Abstract Poster Presenter: Maja Ivanovic, MD (she/her/hers) – University of Chicago Medical Center
10:30 AM - 12:30 PM Central Time

Checkpoint Inhibitor Inflammatory Arthritis: Single Center Case Identification and Chart Validation.
Abstract Poster Presenter: Julia Barasch, MD – Weill Cornell - New York Presbyterian
10:30 AM - 12:30 PM Central Time

Comparing the immunosuppressant burden in immune checkpoint inhibitor mediated inflammatory arthritis versus polymyalgia rheumatica: results from a prospective multicenter registry
Abstract Poster Presenter: Alice Tison, n/a – LBAI, UMR1227, University of Brest, CHU Brest, Brest, France
10:30 AM - 12:30 PM Central Time

Distinct Clinical Phenotypes of Immune Checkpoint Inhibitor–Associated Arthritis: Comparative Analysis of Inflammatory Arthritis, Polymyalgia Rheumatica-like, Activated Crystalline, and Activated Osteoarthritis
Abstract Poster Presenter: Heba Altarawneh, MD – Massachusetts General Hospital
10:30 AM - 12:30 PM Central Time

Evaluation Of The Global Toxicity Burden In Patients Treated With Checkpoint Inhibitors Addressed For a Rheumatologic Toxicity And Its Impact On Oncological Outcomes
Abstract Poster Presenter: Samuel Bitoun, MD, PhD – Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, FHU CARE, Inserm UMR 1184
10:30 AM - 12:30 PM Central Time

Faster Ellipsoid Zone Loss in Hydroxychloroquine Retinopathy with Tapering versus Discontinuation: A Longitudinal Optical Coherence Tomography Study from a Single Center in Taiwan
Abstract Poster Presenter: KO JEN LEE, MD, PhD – National Taiwan University Hospital
10:30 AM - 12:30 PM Central Time

Immune checkpoint inhibitor–associated myocarditis: Incidence, risk factors, and clinical outcomes in a global real-world cohort
Abstract Poster Presenter: Qi Wang, MD – Metrohealth System/Case Western Reserve University
10:30 AM - 12:30 PM Central Time

Immune Checkpoint Inhibitors and Cardiovascular Risk in Patients with Rheumatoid Arthritis and Cancer
Abstract Poster Presenter: KEVIN SHENG- KAI MA, DDS – Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
10:30 AM - 12:30 PM Central Time

Impact of IL-6 Receptor and JAK Inhibitors on Humoral Immunity in Inflammatory Rheumatic Diseases: An Ambispective Study.
Abstract Poster Presenter: Elisabet Perea-Martínez, MD – Rheumatology section, Hospital General Universitario de Elda
10:30 AM - 12:30 PM Central Time

Increased Risk of Azathioprine-Induced Leukopenia in Patients with Systemic Lupus Erythematosus: A 10-Year Retrospective Cohort Study at a Quaternary Care Hospital in Thailand
Abstract Poster Presenter: Settawut Buadee, MD – Faculty of Medicine, Siriraj Hospital, Mahidol university, Thailand
10:30 AM - 12:30 PM Central Time

Inflammatory Arthritis after Hematopoietic Stem Cell Transplant: A Case Series and Literature Review
Abstract Poster Presenter: Scott Yeudall, MD, PhD – The Johns Hopkins Hospital
10:30 AM - 12:30 PM Central Time

Latent Class Analysis Identifies Distinct Phenotypes of Multisystem Immune-Related Adverse Events Predictive of Survival After Immune Checkpoint Inhibitors
Abstract Poster Presenter: Tao Ming Sim, MBBS – National University Hospital
10:30 AM - 12:30 PM Central Time

Microbial activation of cytotoxic CD8⁺ T cells promotes skin immune-related adverse events in patients treated with immune checkpoint inhibitors
Abstract Poster Presenter: Shady Younis, PhD – Stanford University
10:30 AM - 12:30 PM Central Time

Multi-omics Integration Analysis of the Cross-scale Mechanism of MTX-induced T2DM Risk and the Precise Intervention Strategy of Leonurine
Abstract Poster Presenter: Qiang Xu, n/a – Guangzhou University of Traditional Chinese Medicine
10:30 AM - 12:30 PM Central Time

Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic review and meta-analysis highlighting differences with the idiopathic forms
Abstract Poster Presenter: Elvis Hysa, MD – University of Genova
10:30 AM - 12:30 PM Central Time

Prior history of arthritis and PD-1 over PD-L1 blockade predispose to immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
Abstract Poster Presenter: Binod Kc, MBBS – SUNY Upstate Medical University
10:30 AM - 12:30 PM Central Time

Quantitative Immunoglobulin Screening Prior to Rituximab Initiation: A Retrospective Cohort Study
Abstract Poster Presenter: Amelia Khoo, M.D., M.Eng (she/her/hers) – Yale University
10:30 AM - 12:30 PM Central Time

Rituximab Associated Risk for Progressive Multifocal Leukoencephalopathy Among Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Abstract Poster Presenter: Blake Baay, BS – UT Southwestern
10:30 AM - 12:30 PM Central Time

Safety and Effectiveness of Hydroxychloroquine in the Treatment of Rheumatic Immune-Related Adverse Events
Abstract Poster Presenter: Grace Haeun Lee, BA – Massachusetts General Hospital
10:30 AM - 12:30 PM Central Time

Safety Profile of ICIs in Patients with Rheumatoid Arthritis: Results from a Propensity Score-Matched Cohort Study
Abstract Poster Presenter: Betul Ibis, MD (she/her/hers) – Mount Auburn Hospital/Harvard Medical School
10:30 AM - 12:30 PM Central Time

Second-line Therapy for Immune-checkpoint Inhibitor-induced Pneumonitis
Abstract Poster Presenter: Sarah Sun, MD, PhD – Stanford University
10:30 AM - 12:30 PM Central Time

Synergistic Effects of IL-17F and IL-17A on Neutrophil Chemotaxis: Increased Risk of Candidiasis with Dual Blockade of IL-17A and IL17-F
Abstract Poster Presenter: Siba Raychaudhuri, MD – UC Davis, School of Medicine/ VA Medical Center, Sacramento
10:30 AM - 12:30 PM Central Time

Tolerability of Apremilast: Gastrointestinal Side Effects Dominate While Cardiac Safety Remains Reassuring
Abstract Poster Presenter: Francisco Arias, MD – University of Texas Rio Grande Valley
10:30 AM - 12:30 PM Central Time

Tolerance of non-TNF α treatments in patient with an inflammatory rheumatic (IRD) and autoimmune demyelinating diseases: French retrospective cases series
Abstract Poster Presenter: dellal azeddine, n/a (he/him/his) – GHI LE RAINCY MONTFERMEIL
10:30 AM - 12:30 PM Central Time

Tumor outcomes and arthritis flares in patients with pre-existing rheumatoid arthritis receiving immune checkpoint inhibitor therapy
Abstract Poster Presenter: Madalyn Walsh, MD, BS – University of Iowa
10:30 AM - 12:30 PM Central Time

Unsupervised characterization of immune checkpoint inhibitor induced inflammatory arthritis using cluster and latent class analysis: result from a multicenter prospective registry
Abstract Poster Presenter: Alice Tison, n/a – LBAI, UMR1227, University of Brest, CHU Brest, Brest, France
10:30 AM - 12:30 PM Central Time

Validation of the Health Assessment Questionnaire Disability Index in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Abstract Poster Presenter: Kayla Chubbs, MD – Dalhousie University